5:53 PM
 | 
Jul 12, 2012
 |  BC Extra  |  Clinical News

Apremilast meets Phase III endpoint

Celgene Corp. (NASDAQ:CELG) said oral apremilast met the primary endpoint of improving the proportion of patients achieving an ACR20 response at week 16 vs. placebo in the Phase III PALACE-1 trial to treat psoriatic arthritis. The double-blind, international trial enrolled about 500 patients with active psoriatic arthritis who had...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >